Pauline Gee has become vice president and general manager, and Anosheh Amery vice president of sales and marketing of the biosystems division at CeMines, the company said last week.
Gee joins CeMines from MDS Pharma Services, where she was vice president of predictive biology, responsible for directing the company's chemogenomics and toxicogenomics efforts. She holds a PhD in free radical chemistry from Simon Fraser University in British Columbia, Canada.
Amery comes to CeMines from Invitrogen, where he directed the launch of more than 15 new products and managed the evaluation and strategic planning of new business opportunities. Prior to Invitrogen, Amery was at Qiagen. He holds a bachelor of science degree in physiological sciences from UCLA and an MBA from SDA Bocconni in Milan, Italy.
Kalypsys said last week that it has appointed Paul Grint as chief medical officer and head of development.
Prior to joining Kalypsys, Grint was senior vice president and chief medical officer of biopharmaceutical firm Zephyr Sciences. He also has held similar positions at Pfizer, IDEC Pharmaceuticals, and Schering-Plough.
Michael Monko has become vice president of sales for the research products segment of Serologicals, the company said last week. That segment consists of Chemicon International and the Upstate Group.
Monko, who will be based in the company's Temecula, Calif. office, comes to Serologicals from Invitrogen, where he held a number of sales positions. Most recently, he was the senior director of sales force effectiveness. He holds an MBA from Babson College in Wellesley, Mass., and a bachelor of science in biochemistry from the University of New Hampshire.
Invitrogen recently announced additions to its CellSensor cell lines, including those encoding ISRE, c-fos, AP-1, HRE, SIE, and GAS response elements. There are now 23 CellSensor cell lines, Invitrogen said.